The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a sell-off drove the stock price down over 40% to its current level of around $119...
The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a sell-off drove the stock price down over 40% to its current level of around $119...
Share this Article
Recommended